<?xml version="1.0" encoding="UTF-8"?>
<ref id="B109">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Yamamoto</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Matsuyama</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Takeda</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Kawaguchi</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Inoue</surname>
    <given-names>J.-I.</given-names>
   </name>
   <etal/>
  </person-group> (
  <year>2016</year>). 
  <article-title>Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay</article-title>. 
  <source>Antimicrob. Agents Chemother.</source>
  <volume>60</volume> (
  <issue>11</issue>), 
  <fpage>6532</fpage>â€“
  <lpage>6539</lpage>. 
  <pub-id pub-id-type="doi">10.1128/AAC.01043-16</pub-id>
  <pub-id pub-id-type="pmid">27550352</pub-id>
 </mixed-citation>
</ref>
